Physician profile
Christopher E Wilson
NPI 1912494717
$7,887.06
in general payments reported to CMS, 2019-2025
11 companies · $2,823 in 2025
The $2,823 reported for 2025 was more than what 88% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,559 · 2023: $1,216 · 2024: $1,288 · 2025: $2,823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,166 · Travel and Lodging: $1,162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,165.62 |
| Travel and Lodging | $1,161.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,579.06 | 2022-2025 | Intellis Adaptivestim, Inceptiv |
| Boston Scientific Corporation | $1,758.89 | 2023-2025 | General - Pain Management, Superion Indirect Decompression System, Wavewriter Alpha Prime 16 |
| Nevro Corp. | $933.26 | 2023-2024 | Senza |
| Foundation Fusion Solutions, LLC | $506.61 | 2025 | |
| Globus Medical, INC. | $464.70 | 2025 | Senza, Omnia |
| Collegium Pharmaceutical, INC. | $247.92 | 2023-2024 | Xtampza, Belbuca |
| Abbott Laboratories | $153.90 | 2025 | Eterna, Proclaim |
| Spr Therapeutics, INC | $80.81 | 2024 | Sprint Pns System |
| Nalu Medical, INC. | $73.54 | 2025 | Nalu Neurostimulation System |
| Painteq LLC | $53.65 | 2023 | Painteq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.72 | 2023-2024 | Relistor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.